充血除去剤の世界市場：製品タイプ・処方区分・カテゴリー・用途・年齢層・流通チャネル・地域別 (～2035年)

世界の充血除去剤の市場規模は、2024年の289億6,535万米ドルから、予測期間中はCAGR 6.48％で着実に推移し、2035年には578億1,082万米ドルに成長すると予測されています。

充血除去剤は、鼻腔内の腫れた組織を縮小させることで、鼻づまりや閉塞感から一時的に解放する薬です。血管をターゲットにして腫れを抑え、呼吸をしやすくします。OTCとして広く販売されており、風邪、アレルギー性鼻炎、副鼻腔関連の症状に使用されています。

呼吸器疾患は依然として世界中で主要な健康問題のひとつであり、そのため充血除去剤の需要は医療市場において最も高い位置を占め続けています。風邪、インフルエンザ、花粉症、副鼻腔炎といった症例の増加は長らく続いており、都市部の大気汚染によってさらに悪化しています。これにより、点鼻スプレー、経口剤、吸入薬の消費が増加しています。特にPMやNO2といった呼吸器汚染物質は、既存の慢性呼吸器疾患を悪化させる要因となり、患者は充血除去剤療法に大きく依存しています。こうした需要は持続的であるだけでなく、季節性の流行によってさらに拡大しています。先進国、新興国を問わず呼吸器疾患が増加する中、充血除去剤市場はセルフケア医療ソリューションの必要不可欠なセグメントとして拡大を続けています。

地域別分析

北米市場は、小売薬局やEコマースプラットフォームを通じた充血除去剤の広範なアベイラビリティに支えられています。副鼻腔炎や喘息の高い有病率も継続的な製品需要を牽引しています。2024年に109億7,578万米ドルに達すると見込まれる北米市場の強固な地位は、先進的な流通ネットワークと、季節性アレルギーに対する充血除去剤への高い消費者依存を反映しています。

寒冷な気候によって呼吸器疾患が多い欧州では、充血除去剤需要が高まっています。点鼻スプレー、点鼻薬、経口充血除去剤が堅固な医薬品供給網によって常に安定的に供給されています。2024年に86億4,187万米ドルに達すると予測される欧州市場は、セルフケア行動の増加と市販薬を支援する法律により、安定した需要を示しています。

アジア太平洋地域は、大気汚染が主要な呼吸器疾患の原因となっていることから急速に拡大しています。OTC医薬品は、東南アジアやインドの中間層コミュニティでますます人気が高まっています。2024年に69億6,703万米ドルと評価されるアジア太平洋市場は、都市化や所得水準の上昇によって、市販薬や処方用充血除去剤の利用が増加し、急速な成長を遂げています。

当レポートでは、世界の充血除去剤の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 市場イントロダクション

第3章 調査手法

第4章 市場力学

• 促進要因
  • 呼吸器疾患の発生率の増加
  • 自己治療の人気が高まる
• 抑制要因
  • 厳格な規制ガイドライン
  • 充血除去剤に伴う副作用と安全性の懸念
• 機会
  • 天然およびハーブの充血除去剤の需要増加
  • 複数の症状を対象とした併用療法の開発
• COVID-19の影響分析

第5章 市場要因分析

• サプライチェーン/バリューチェーン分析
• ポーターのファイブフォースモデル

第6章 世界の充血除去剤市場：製品タイプ別

• 合成充血除去剤
• 芳香性充血除去剤
• ハーブ充血除去剤
• 併用剤

第7章 世界の充血除去剤市場：処方区分別

• 鼻腔
• 経口
• 局所

第8章 世界の充血除去剤市場：カテゴリー別

• 処方薬
• OTC薬

第9章 世界の充血除去剤市場：用途別

• アレルギー性鼻炎
• 風邪
• 喘息
• 鼻炎
• 副鼻腔炎
• 鼻ポリープ
• その他

第10章 世界の充血除去剤市場：年齢層別

• 小児科
• 老年医学

第11章 世界の充血除去剤市場：流通チャネル別

• 病院薬局
• ドラッグストア・薬局
• オンライン薬局

第12章 世界の充血除去剤市場：地域別

• 北米
• 欧州
• アジア太平洋
• 南米
• 中東・アフリカ

第13章 競合情勢

• 市場シェア分析

第14章 企業プロファイル

• PFIZER.
• CIPLA LTD.
• GLAXOSMITHKLINE（GSK）/PANADOL
• JOHNSON & JOHNSON
• APTARGROUP, INC.
• PROCTOR & GAMBLE COMPANY
• RECKITT BENCKISER GROUP PLC
• SANOFI
• PERRIGO COMPANY PLC
• DR. REDDY'S LABORATORIES

第15章 データの引用

LIST OF TABLES

• TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
• TABLE 2 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 3 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 4 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 5 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 6 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 7 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 8 GLOBAL DECONGESTANT ESTIMATES & FORECAST, BY REGION, 2019-2035 (USD MILLION)
• TABLE 9 NORTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 10 NORTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 11 NORTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 12 NORTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 13 NORTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 14 NORTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 15 US DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 16 US DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 17 US DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 18 US DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 19 US DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 20 US DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 21 CANADA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 22 CANADA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 23 CANADA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 24 CANADA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 25 CANADA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 26 CANADA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 27 MEXICO DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 28 MEXICO DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 29 MEXICO DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 30 MEXICO DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 31 MEXICO DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 32 MEXICO DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 33 EUROPE DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 34 EUROPE DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 35 EUROPE DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 36 EUROPE DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 37 EUROPE DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 38 EUROPE DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 39 GERMANY DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 40 GERMANY DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 41 GERMANY DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 42 GERMANY DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 43 GERMANY DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 44 GERMANY DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 45 UK DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 46 UK DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 47 UK DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 48 UK DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 49 UK DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 50 UK DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 51 FRANCE DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 52 FRANCE DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 53 FRANCE DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 54 FRANCE DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 55 FRANCE DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 56 FRANCE DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 57 ITALY DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 58 ITALY DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION
• TABLE 59 ITALY DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 60 ITALY DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 61 ITALY DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 62 ITALY DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 63 SPAIN DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 64 SPAIN DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 65 SPAIN DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 66 SPAIN DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION
• TABLE 67 SPAIN DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 68 SPAIN DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 69 TURKEY DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 70 TURKEY DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 71 TURKEY DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 72 TURKEY DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 73 TURKEY DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 74 TURKEY DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 75 REST OF EUROPE DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 76 REST OF EUROPE DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 77 REST OF EUROPE DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 78 REST OF EUROPE DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 79 REST OF EUROPE DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 80 REST OF EUROPE DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 81 ASIA-PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 82 ASIA-PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 83 ASIA-PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 84 ASIA-PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 85 ASIA-PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 86 ASIA-PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 87 JAPAN DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 88 JAPAN DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 89 JAPAN DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 90 JAPAN DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 91 JAPAN DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 92 JAPAN DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 93 CHINA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 94 CHINA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 95 CHINA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 96 CHINA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 97 CHINA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 98 CHINA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 99 INDIA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 100 INDIA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 101 INDIA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 102 INDIA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 103 INDIA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 104 INDIA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 105 SOUTH KOREA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 106 SOUTH KOREA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 107 SOUTH KOREA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 108 SOUTH KOREA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 109 SOUTH KOREA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 110 SOUTH KOREA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 111 INDONESIA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 112 INDONESIA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 113 INDONESIA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 114 INDONESIA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 115 INDONESIA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 116 INDONESIA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 117 MALAYSIA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 118 MALAYSIA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 119 MALAYSIA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 120 MALAYSIA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 121 MALAYSIA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 122 MALAYSIA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 123 AUSTRALIA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 124 AUSTRALIA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 125 AUSTRALIA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 126 AUSTRALIA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 127 AUSTRALIA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 128 AUSTRALIA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 129 SINGAPORE DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 130 SINGAPORE DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 131 SINGAPORE DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 132 SINGAPORE DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 133 SINGAPORE DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 134 SINGAPORE DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 135 REST OF ASIA PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 136 REST OF ASIA PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 137 REST OF ASIA PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 138 REST OF ASIA PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 139 REST OF ASIA PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 140 REST OF ASIA PACIFIC DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 141 SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 142 SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 143 SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 144 SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 145 SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 146 SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 147 BRAZIL DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 148 BRAZIL DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 149 BRAZIL DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 150 BRAZIL DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 151 BRAZIL DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 152 BRAZIL DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 153 ARGENTINA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 154 ARGENTINA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 155 ARGENTINA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 156 ARGENTINA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 157 ARGENTINA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 158 ARGENTINA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 159 REST OF SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 160 REST OF SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 161 REST OF SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 162 REST OF SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 163 REST OF SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 164 REST OF SOUTH AMERICA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 165 MIDDLE EAST & AFRICA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 166 MIDDLE EAST & AFRICA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 167 MIDDLE EAST & AFRICA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 168 MIDDLE EAST & AFRICA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 169 MIDDLE EAST & AFRICA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 170 MIDDLE EAST & AFRICA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 171 SOUTH AFRICA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 172 SOUTH AFRICA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 173 SOUTH AFRICA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 174 SOUTH AFRICA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 175 SOUTH AFRICA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 176 SOUTH AFRICA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 177 GCC COUNTRIES DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 178 GCC COUNTRIES DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 179 GCC COUNTRIES DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 180 GCC COUNTRIES DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 181 GCC COUNTRIES DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 182 GCC COUNTRIES DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 183 SAUDI ARABIA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 184 SAUDI ARABIA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 185 SAUDI ARABIA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 186 SAUDI ARABIA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 187 SAUDI ARABIA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 188 SAUDI ARABIA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 189 REST OF MIDDLE EAST AND AFRICA DECONGESTANT ESTIMATES & FORECAST, BY PRODUCT TYPE, 2019-2035 (USD MILLION)
• TABLE 190 REST OF MIDDLE EAST AND AFRICA DECONGESTANT ESTIMATES & FORECAST, BY FORMULATION, 2019-2035 (USD MILLION)
• TABLE 191 REST OF MIDDLE EAST AND AFRICA DECONGESTANT ESTIMATES & FORECAST, BY CATEGORY, 2019-2035 (USD MILLION)
• TABLE 192 REST OF MIDDLE EAST AND AFRICA DECONGESTANT ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 193 REST OF MIDDLE EAST AND AFRICA DECONGESTANT ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD MILLION)
• TABLE 194 REST OF MIDDLE EAST AND AFRICA DECONGESTANT ESTIMATES & FORECAST, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION)
• TABLE 195 PFIZER. COMPANY: PRODUCTS OFFERED
• TABLE 196 CIPLA LTD. PRODUCTS OFFERED
• TABLE 197 GLAXOSMITHKLINE (GSK)/ PANADOL : PRODUCTS OFFERED
• TABLE 198 JOHNSON & JOHNSON: PRODUCTS OFFERED
• TABLE 199 APTARGROUP, INC. COMPANY: PRODUCTS OFFERED
• TABLE 200 PROCTOR & GAMBLE COMPANY PRODUCTS OFFERED
• TABLE 201 RECKITT BENCKISER GROUP PLC CHEMICAL LTD: PRODUCTS OFFERED
• TABLE 202 SANOFI: PRODUCTS OFFERED
• TABLE 203 PERRIGO COMPANY PLC: PRODUCTS OFFERED
• TABLE 204 DR. REDDY'S LABORATORIES: PRODUCTS OFFERED

LIST OF FIGURES

• FIGURE 1 GLOBAL DECONGESTANT MARKET (BY REGION), 2024
• FIGURE 2 GLOBAL DECONGESTANT MARKET: STRUCTURE
• FIGURE 3 PORTER'S FIVE FORCES ANALYSIS OF THE DECONGESTANT
• FIGURE 4 GLOBAL DECONGESTANT MARKET, BY PRODUCT TYPE, 2024 (% SHARE)
• FIGURE 5 GLOBAL DECONGESTANT MARKET, BY FORMULATION, 2024 (% SHARE)
• FIGURE 6 GLOBAL DECONGESTANT MARKET, BY CATEGORY, 2024 (% SHARE)
• FIGURE 7 GLOBAL DECONGESTANT MARKET, BY APPLICATION, 2024 (% SHARE)
• FIGURE 8 GLOBAL DECONGESTANT MARKET, BY AGE GROUP, 2024 (% SHARE)
• FIGURE 9 GLOBAL DECONGESTANT MARKET, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
• FIGURE 10 GLOBAL DECONGESTANT MARKET MAJOR PLAYERS MARKET SHARE ANALYSIS, 2024 (%)
• FIGURE 11 PFIZER. COMPANY: SWOT ANALYSIS
• FIGURE 12 CIPLA LTD. SWOT ANALYSIS
• FIGURE 13 GLAXOSMITHKLINE (GSK)/ PANADOL : SWOT ANALYSIS
• FIGURE 14 JOHNSON & JOHNSON: SWOT ANALYSIS
• FIGURE 15 APTARGROUP, INC. COMPANY: SWOT ANALYSIS
• FIGURE 16 PROCTOR & GAMBLE COMPANY SWOT ANALYSIS
• FIGURE 17 RECKITT BENCKISER GROUP PLC CHEMICAL LTD: SWOT ANALYSIS
• FIGURE 18 SANOFI: SWOT ANALYSIS
• FIGURE 19 PERRIGO COMPANY PLC: SWOT ANALYSIS
• FIGURE 20 DR. REDDY'S LABORATORIES: SWOT ANALYSIS

Global Decongestant Market Research Report by Product Type (Synthetic Decongestants, Aromatic Decongestants, Herbal Decongestants, Combination), by Formulation (Nasal, Oral, Topical), by Category (Prescription Based, Over the Counter), by Application (Nasal Allergies, Cold, Asthma, Rhinits, Sinusitis, Nasal Polyps, Others), by Age Group (Peditrics, Adults, Geriatrics), by Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies), and by Region (North America, Europe, Asia Pacific, South America, Middle East and Africa) Forecast till 2035

Industry Overview

The global decongestant market will witness steady growth, increasing from USD 28,965.35 million in 2024 to USD 57,810.82 million in 2035, at a 6.48% CAGR throughout 2025-2035. Decongestants are drugs that provide temporary relief from blocked or stuffy noses by shrinking swollen tissues inside the nasal passages. They target blood vessels to reduce swelling and allow easier breathing. Widely sold as over-the-counter remedies, they are used for common colds, allergic rhinitis, and sinus-related issues.

Respiratory diseases are still among the major health concerns all over the earth, which is the reason why the need for decongestants still holds the highest place in the healthcare market. The rising frequency of colds, flu, hay fever, and sinus infections, which is a trend that has been going on for a while and worsened by urban air pollution, has been driving the consumption of nasal sprays, oral tablets, and inhalers. Respiratory pollutants such as PM and NO2 are tailored to trigger the already chronic respiratory disorders in patients who thus rely heavily on decongestant therapies. The demand is not only persistent but also augmented by seasonal outbreaks. The market for healthcare continues to expand as a necessary segment of self-care healthcare solutions, as respiratory cases surge in both developed and underdeveloped worlds.

Key Company Development

Sanofi takes significant steps in the decongestant industry with innovation and strategic expansion. They are stimulating their R&D efforts to attract the launch of the very first photo-sensitive formulations, including variants of multi-symptom combination therapies and natural decongestants. The trend with consumers towards safety and holistic treatment is exactly the direction that the Sanofi company is taking. Sanofi is also leveraging strategic collaborations with healthcare providers and emerging startups to strengthen its position in the growing herbal and alternative remedies segment. To further diversify its portfolio, the company is considering acquisitions of firms with established expertise in natural ingredient-based products.

Key Players

Major players in the global decongestant market are Pfizer, Johnson & Johnson, Sanofi, Cipla Ltd, AptarGroup, Inc., Perrigo Company PLC, PANADOL, and Procter & Gamble Company.

Report Attribute Details

Market Size 2024 USD 28,965.35 Million

Market Size 2035 USD 57,810.82 Million

CAGR (2025-2035) 6.48%

Base Year 2024

Market Forecast Period 2025-2035

Historical Data 2019-2024

Market Segmentations

By Product Type: Synthetic Decongestants - 6.35%, Aromatic Decongestants - 6.56%.

By Formulation: Nasal - 6.61%, Oral - 6.74%.

By Category: Prescription-Based - 6.04%, Over the Counter - 6.64%

By Application: Nasal Allergies - 6.75%, Cold - 6.72%.

By Age Group: Pediatrics - 6.96%, Adults - 6.64%

By Distribution Channel: Hospital Pharmacies - 6.02%, Drug Stores & Retail Pharmacies - 6.62%.

Regional Analysis

The North American market benefits from the widespread availability of decongestants through retail pharmacies and e-commerce platforms. High prevalence of sinusitis and asthma drives consistent product demand. North America's strong position, reaching USD 10,975.78 million in 2024, reflects advanced distribution networks and high consumer reliance on decongestants for seasonal allergies.

Europe's cold weather, which makes respiratory disorders more common, contributes to the continent's need for decongestants. Nasal sprays, drops, and oral decongestants are consistently available because of robust pharmaceutical supply chains. With USD 8,641.87 million, Europe shows consistent demand bolstered by more self-care behaviors and supportive laws for over-the-counter medications.

The market is expanding rapidly in the Asia-Pacific region due to urban air pollution, which is a major cause of respiratory issues. OTC drugs are becoming more and more popular among Southeast Asian and Indian middle-class communities. With a valuation of USD 6,967.03 million, the Asia Pacific market is growing quickly as the usage of over-the-counter and prescription decongestants is increased by urbanization and rising income levels.

South America is showing steady growth, supported by increasing healthcare spending and greater awareness of respiratory treatments. Brazil's large population makes it the dominant market, while Argentina and Chile show growing preference for OTC drugs. Rising internet penetration is also boosting online sales of decongestants.

Rising healthcare expenditure and a growing focus on accessible medicines are driving the MEA market. Gulf Cooperation Council (GCC) countries are emerging as strong contributors with the rapid adoption of modern pharmacy networks. Africa is gradually overcoming barriers of affordability and accessibility, making decongestants more widely available.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 RESEARCH OBJECTIVE
• 2.3 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 DATA MINING PROCESS
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 SECONDARY RESEARCH DATA FLOW:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
  • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 CONSUMPTION & NET TRADE APPROACH
  • 3.6.2 REVENUE ANALYSIS APPROACH
• 3.7 DATA FORECASTING
  • 3.7.1 DATA FORECASTING TECHNIQUE
• 3.8 DATA MODELING
  • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 3.8.2 DATA MODELING:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
  • 4.1.1 INNOVATION IN DRUG FORMULATIONS AND DELIVERY SYSTEMS
  • 4.1.2 HEALTHCARE ACCESSIBILITY AND REGULATION
  • 4.1.3 RISING DEMAND FOR NASAL SPRAYS AND INHALERS
• 4.2 DRIVERS
  • 4.2.1 INCREASING INCIDENCE OF RESPIRATORY DISEASES
  • 4.2.2 GROWING POPULARITY OF SELF-MEDICATION
• 4.3 RESTRAINTS
  • 4.3.1 STRINGENT REGULATORY GUIDELINES
  • 4.3.2 SIDE EFFECTS AND SAFETY CONCERNS ASSOCIATED WITH DECONGESTANTS
• 4.4 OPPORTUNITY
  • 4.4.1 INCREASED DEMAND FOR NATURAL AND HERBAL DECONGESTANTS
  • 4.4.2 DEVELOPMENT OF COMBINATION THERAPIES TARGETING MULTIPLE SYMPTOMS
• 4.5 IMPACT ANALYSIS OF COVID-19
  • 4.5.1 IMPACT ON OVERALL HEALTHCARE
  • 4.5.2 IMPACT ON GLOBAL DECONGESTANT MARKET
  • 4.5.3 IMPACT ON SUPPLY CHAIN OF GLOBAL DECONGESTANT MARKET
  • 4.5.4 IMPACT ON MARKET DEMAND OF GLOBAL DECONGESTANT MARKET
  • 4.5.5 IMPACT ON PRICING OF GLOBAL DECONGESTANT MARKET

5 MARKET FACTOR ANALYSIS

• 5.1 SUPPLY/VALUE CHAIN ANALYSIS
  • 5.1.1 RAW MATERIAL PROCUREMENT
  • 5.1.2 MANUFACTURING
  • 5.1.3 PACKAGING & LABELLING
  • 5.1.4 DISTRIBUTION AND RETAIL
  • 5.1.5 RETAIL & CONSUMER DEMAND
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 THREAT OF SUBSTITUTES
  • 5.2.3 BARGAINING POWER OF SUPPLIERS
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY

6 GLOBAL DECONGESTANT MARKET, BY PRODUCT TYPE

• 6.1 INTRODUCTION
  • 6.1.1 SYNTHETIC DECONGESTANTS
  • 6.1.2 AROMATIC DECONGESTANTS
  • 6.1.3 HERBAL DECONGESTANTS
  • 6.1.4 COMBINATION

7 GLOBAL DECONGESTANT MARKET, BY FORMULATION

• 7.1 INTRODUCTION
  • 7.1.1 NASAL
    • 7.1.1.1 NASAL SPRAY
    • 7.1.1.2 NASAL DROPS
    • 7.1.1.3 INHALERS
  • 7.1.2 ORAL
    • 7.1.2.1 TABLETS & CAPSULES
    • 7.1.2.2 LIQUIDS & SYRUPS
  • 7.1.3 TOPICAL
    • 7.1.3.1 GELS
    • 7.1.3.2 PATCHES

8 GLOBAL DECONGESTANT MARKET, BY CATEGORY

• 8.1 INTRODUCTION
  • 8.1.1 PRESCRIPTION-BASED
  • 8.1.2 OVER THE COUNTER

9 GLOBAL DECONGESTANT MARKET, BY APPLICATION

• 9.1 INTRODUCTION
  • 9.1.1 NASAL ALLERGIES
  • 9.1.2 COLD
  • 9.1.3 ASTHMA
  • 9.1.4 RHINITIS
  • 9.1.5 SINUSITIS
  • 9.1.6 NASAL POLYPS
  • 9.1.7 OTHERS

10 GLOBAL DECONGESTANT MARKET, BY AGE GROUP

• 10.1 INTRODUCTION
  • 10.1.1 PEDIATRICS
  • 10.1.2 GERIATRICS

11 GLOBAL DECONGESTANT MARKET, BY DISTRIBUTION CHANNEL

• 11.1 INTRODUCTION
  • 11.1.1 HOSPITAL PHARMACIES
  • 11.1.2 DRUG STORES & RETAIL PHARMACIES
  • 11.1.3 ONLINE PHARMACIES

12 GLOBAL DECONGESTANT MARKET, BY REGION

• 12.1 INTRODUCTION
  • 12.1.1 NORTH AMERICA
    • 12.1.1.1 US
    • 12.1.1.2 CANADA
    • 12.1.1.3 MEXICO
  • 12.1.2 EUROPE
    • 12.1.2.1 GERMANY
    • 12.1.2.2 UK
    • 12.1.2.3 FRANCE
    • 12.1.2.4 ITALY
    • 12.1.2.5 SPAIN
    • 12.1.2.6 TURKEY
    • 12.1.2.7 REST OF EUROPE
  • 12.1.3 ASIA-PACIFIC
    • 12.1.3.1 JAPAN
    • 12.1.3.2 CHINA
    • 12.1.3.3 INDIA
    • 12.1.3.4 SOUTH KOREA
    • 12.1.3.5 INDONESIA
    • 12.1.3.6 MALAYSIA
    • 12.1.3.7 AUSTRALIA
    • 12.1.3.8 SINGAPORE
    • 12.1.3.9 REST OF ASIA PACIFIC
  • 12.1.4 SOUTH AMERICA
    • 12.1.4.1 BRAZIL
    • 12.1.4.2 ARGENTINA
    • 12.1.4.3 REST OF SOUTH AMERICA
  • 12.1.5 MIDDLE EAST & AFRICA
    • 12.1.5.1 SOUTH AFRICA
    • 12.1.5.2 GCC COUNTRIES
    • 12.1.5.3 SAUDI ARABIA
    • 12.1.5.4 REST OF MIDDLE EAST AND AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 MARKET SHARE ANALYSIS, 2024

14 COMPANY PROFILES

• 14.1 PFIZER.
  • 14.1.1 COMPANY OVERVIEW
  • 14.1.2 PRODUCTS OFFERED
  • 14.1.3 SWOT ANALYSIS
  • 14.1.4 KEY STRATEGY
• 14.2 CIPLA LTD.
  • 14.2.1 COMPANY OVERVIEW
  • 14.2.2 PRODUCTS OFFERED
  • 14.2.3 SWOT ANALYSIS
  • 14.2.4 KEY STRATEGY
• 14.3 GLAXOSMITHKLINE (GSK)/ PANADOL
  • 14.3.1 COMPANY OVERVIEW
  • 14.3.2 PRODUCTS OFFERED
  • 14.3.3 SWOT ANALYSIS
  • 14.3.4 KEY STRATEGY
• 14.4 JOHNSON & JOHNSON
  • 14.4.1 COMPANY OVERVIEW
  • 14.4.2 PRODUCTS OFFERED
  • 14.4.3 SWOT ANALYSIS
  • 14.4.4 KEY STRATEGY
• 14.5 APTARGROUP, INC.
  • 14.5.1 COMPANY OVERVIEW
  • 14.5.2 PRODUCTS OFFERED
  • 14.5.3 SWOT ANALYSIS
  • 14.5.4 KEY STRATEGY
• 14.6 PROCTOR & GAMBLE COMPANY
  • 14.6.1 COMPANY OVERVIEW
  • 14.6.2 PRODUCTS OFFERED
  • 14.6.3 SWOT ANALYSIS
  • 14.6.4 KEY STRATEGY
• 14.7 RECKITT BENCKISER GROUP PLC
  • 14.7.1 COMPANY OVERVIEW
  • 14.7.2 PRODUCTS OFFERED
  • 14.7.3 SWOT ANALYSIS
  • 14.7.4 KEY STRATEGY
• 14.8 SANOFI
  • 14.8.1 COMPANY OVERVIEW
  • 14.8.2 PRODUCTS OFFERED
  • 14.8.3 SWOT ANALYSIS
  • 14.8.4 KEY STRATEGY
• 14.9 PERRIGO COMPANY PLC
  • 14.9.1 COMPANY OVERVIEW
  • 14.9.2 PRODUCTS OFFERED
  • 14.9.3 SWOT ANALYSIS
  • 14.9.4 KEY STRATEGY
• 14.10 DR. REDDY'S LABORATORIES
  • 14.10.1 COMPANY OVERVIEW
  • 14.10.2 PRODUCTS OFFERED
  • 14.10.3 SWOT ANALYSIS
  • 14.10.4 KEY STRATEGY

15 DATA CITATIONS